Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Vorinostat with FLAG in relapsed/refractory AML
NCT02412475Phase 1Terminated
- Start
- Feb 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of decitabine in acute myeloid leukemia (AML). Primary endpoint: Complete Remission at 60 days. Started Feb 2015; status: terminated.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02412475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02412475.